Case Studies
Opportunity Assessment for Targeted Therapy– Anti PD-1/PDL-1 Therapy
Life Sciences
With significant R&D community interest to explore targeted checkpoint inhibitors and understand continuous innovations, a top 10 pharma giant approached FutureBridge to conduct an in-depth study to identify the biomarkers, clinical efficacy, and toxicity of the administered Anti PD-1/PDL-1 drugs that would help them to assess the positioning of Anti PD-1/PDL-1 therapy. FutureBridge conducted selective scientific literature reviews and with advanced data digitization tools, provided insights to help the client assess the therapy positioning on a custom compatible database for clinical responses prediction.
210827-Hero-Case-Study-_1-Anti-PD1_PDL-1-Therapy_-Revised
